Jext, a new adrenaline auto-injector (AAI), has been launched by ALK-Abelló for use in the emergency treatment of severe allergic reactions (anaphylaxis) to foods, insect stings or bites, drugs and other allergens, as well as idiopathic or exercise induced anaphylaxis.
“Adrenaline auto-injectors enable patients and carers to administer a dose of adrenaline in an emergency situation, prior to seeking emergency medical attention,” said Dr Adam Fox, a Consultant Paediatric Allergist in London, UK.
“Jext has been developed to address the specific requirements of people needing self-injectable adrenaline.”
Jext has been designed with the following features:
- A 24-month shelf-life from date of manufacture
- A unique automatic locking protective needle shield
- No special temperature storage requirements other than ‘do not freeze’
- Clear labelling and integral instructions for use
- Hard carry case for patient convenience
“The Anaphylaxis Campaign welcomes the increased choice offered by Jext to the range of adrenaline injectors available to patients,” said Lynne Regent, CEO of the Campaign.
“We feel very strongly that adrenaline injectors should be made available to all those affected by anaphylaxis and our organisation offers support and guidance to patients who are prescribed these devices.”
Lindsey McManus, Executive Director of Allergy UK, added: “It is vital that emergency treatment for anaphylaxis is given as quickly and effectively as possible.
“The new features in Jext will give considerable reassurance and confidence to those that need to use an adrenaline auto-injector, whether they are allergic themselves or if they are a carer of someone with severe allergy.”